YJYan Jiang

Yan Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan Jiang has a total of 222 co-authors. Here are the top co-authors by number of shared publications:

  • Weibo Xia

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    50 shared publications
  • Mei Li

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    39 shared publications
  • Ou Wang

    Department of Endocrinology, NHC Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730

    27 shared publications
  • Xiaoping Xing

    Department of Endocrinology, Key Laboratory of Endocrinology, National Health and Family Planning Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing, Beijing

    25 shared publications
  • Xiaoping Xing

    Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

    24 shared publications
  • Ou Wang

    Department of Endocrinology, Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    19 shared publications

Latest Publications

  • Open Access

    Age at Menarche and Osteoporosis: The China Osteoporosis Prevalence Study

    by Yongxuan Wang, Zhixiang Wang, Qichao Sun, Yan Jiang, Yue Chi, Ruizhi Jiajue, Wei Liu, Xiang Li, Qianqian Pang, Ou Wang, et al.

    Menarche marks the onset of high estrogen exposure, yet the relationship between age at menarche (AAM) and osteoporosis is not fully understood. This study aimed to investigate the associations of AAM with bone mineral density (BMD), osteoporosis, and fractures across different age decades. In this cross-sectional study using data from the China Osteoporosis Prevalence Study (COPS), we examined the correlations between AAM and BMD at the femoral neck (FN), total hip (TH), and lumbar spine (LS) in women aged 20-29 to ≥70 years. Peak bone mass was determined based on BMD trends across age groups. Among postmenopausal women, we also assessed the associations of AAM with osteoporosis, vertebral fractures, and clinical fractures within the past five years. This cross-sectional analysis is exploratory and intended to generate hypotheses about the life-course association between AAM and bone health. Later AAM was associated with a a cross-sectional pattern of peak bone mass estimates occurring in older age groups at the FN and TH; however, no significant difference in peak bone mass magnitude was observed between AAM groups. In postmenopausal women, later AAM correlated with lower BMD at the LS and TH, and higher odds of osteoporosis. No significant association with fractures was observed. Later AAM was associated with estimates of peak bone mass timing at older age groups at the FN and TH without altering its magnitude. In postmenopausal women, later AAM was associated with modestly lower LS and TH BMD and higher odds of osteoporosis. Therefore, earlier osteoporosis screening is warranted for these women after menopause, and BMD assessment should include sites beyond the femoral neck.

  • Open Access

    Effectiveness, safety, and pharmacokinetics of burosumab in Chinese children with X-linked hypophosphatemia: an open-label, single-arm phase 4 study

    by Wei Wu, Yan Jiang, Zhenlin Zhang, Li Liu, Wenjuan Qiu, Ying Ji, Maiko Sugimoto, Chinwei Yung, ChenRui Qiu, Masaaki Kuriki, et al.

    Burosumab has shown benefits in treating X-linked hypophosphatemia (XLH), a rare genetic bone disorder that causes rickets among pediatric patients. However, data in Chinese children with XLH are lacking. Therefore, we evaluated the effectiveness, safety, and pharmacokinetics of burosumab among Chinese children (aged 1-12 yr) with XLH in this open-label, multi-center, single-arm, phase 4 study. Of the 28 patients enrolled (12 male, 16 female), 27 completed the study. All patients received s.c. injections of burosumab at a starting dose of 0.8 mg/kg every 2 wk for 64 wk. The mean ± SD patient age was 5.68 ± 3.07 yr. Burosumab treatment increased the serum phosphorus level by 0.96 ± 0.27 mg/dL from baseline during the burosumab dose cycles (average of week 2, 4, 8, 12, 16, 24, 32, 40, 52, and 64). The improvement from baseline (2.33 ± 0.24 mg/dL) to week 64 (3.29 ± 0.30 mg/dL) was significant (p < .05). The Radiograph Global Impression of Change was significantly improved at week 64 (1.90 ± 0.48; p < .0001 vs baseline), and the percentage predicted 6-min walking test among patients aged ≥5 yr with post-baseline values (n = 16) was significantly increased from 67.32% ± 8.27% at baseline to 71.91% ± 8.25% at week 64 (p < .05). All patients experienced treatment-emergent adverse events; most were mild to moderate. In conclusion, burosumab treatment in Chinese children with XLH corrected serum phosphorus levels and improved clinical parameters with tolerable safety profiles.

  • Open Access

    Efficacy and safety of denosumab, zoledronic acid and alendronate on bone mineral density and trabecular bone score in men with osteoporosis

    by Bingna Zhou, Yi Zhang, Wei Yu, Lei Sun, Yanye Wang, Yan Jiang, Ou Wang, Xiaoping Xing, Weibo Xia, Jia Zhang, et al.

    Objective: Osteoporosis in men is a common but often neglected health problem. We aim to compare the efficacy and safety of denosumab, zoledronic acid and alendronate in men with osteoporosis. Methods: In this randomized, comparative, open-label study, 390 men with osteoporosis or osteopenia were included. They were randomized to receive the treatment of denosumab, alendronate, or zoledronic acid for 12 months. The percentage changes in bone mineral density (BMD), trabecular bone score (TBS) and bone turnover biomarkers (BTMs) during the treatment were evaluated. Safety parameters were observed. Results: The baseline characteristics were well balanced among the three groups. After 12 months of treatment, denosumab, alendronate and zoledronic acid significantly increased BMD by 4.83 ± 0.89%, 4.32 ± 0.77%, 5.18 ± 0.73% at lumbar spine, by 2.75 ± 0.51%, 2.50 ± 0.61% and 2.83 ± 0.59% at total hip, TBS was significantly increased by 2.44 ± 0.52%, 2.00 ± 0.64%, 2.29 ± 0.55%, respectively, without significant differences among the three groups. Serum levels of BTMs decreased significantly and similarly in all three groups (all P < .05 vs. baseline). Denosumab and alendronate group had fewer adverse events than zoledronic acid group. Denosumab had similar efficacy in patients with different gonadal functions. In patients previously receiving bone resorption inhibitors, denosumab continued to increase BMD and TBS, but the increments were reduced by approximately 30% in BMD at lumbar spine compared with treatment-naive patients. Conclusion: Denosumab, alendronate and zoledronic acid significantly and similarly reduced BTMs, increased BMD and TBS in men with osteoporosis, whether the gonadal function of patients was normal or decreased. Previous anti-bone resorption therapy may partially diminish the efficacy of denosumab.


  • Open Access

    Association of serum periostin with bone microarchitecture, muscle mass and function in Chinese postmenopausal women

    by Yiyi Gong, Yushuo Wu, Xiaosen Ma, Lijia Cui, Xiang Li, Qianqian Pang, Yue Chi, Ruizhi Jiajue, Wei Liu, Ou Wang, et al.

    Purpose: High serum periostin is linked to an increased risk of osteoporotic fractures in postmenopausal women. However, the relationships between serum periostin and bone microarchitecture, particularly muscle mass, and muscle function remain unclear. This study aims to investigate the relationships between serum periostin and bone mineral density, bone microarchitecture, muscle mass and function, falls, and fractures in community-dwelling Chinese postmenopausal women. Method: Serum periostin levels were measured in 135 Chinese postmenopausal women. Dual-energy X-ray absorptiometry assessed areal bone mineral density (aBMD), lumbar trabecular bone score (TBS), and muscle mass. High-resolution peripheral quantitative computed tomography (HR-pQCT) evaluated bone microarchitecture. Muscle function and fall risk were assessed using handgrip strength, the Short Physical Performance Battery (SPPB), the Timed Up and Go (TUG) test, and the Falls Risk for Older People in the Community (FROP-Com) screening tool. Result: The mean serum periostin was 1770.3 ± 440.4 pmol/L. Serum periostin was negatively correlated with bone microarchitecture parameters, total area (Tot.Ar), cortical perimeter (Ct.Pm), trabecular area (Tb.Ar), estimated bone strength stiffness, and failure load. Negative correlations were also found with appendicular skeletal muscle mass (ASM), balance test scores, and gait speed. Conversely, serum periostin was positively correlated with TUG time and FROP-Com scores. Conclusion: Higher serum periostin is associated with smaller bone cross-sectional area, lower estimated bone strength, reduced muscle mass, and higher fall risk, indicating its potential as a predictor for assessing skeletal and muscular health in postmenopausal women.

  • Clinical and Genetic Profile of Chinese Familial Hypocalciuric Hypercalcemia Type 1 (FHH1): A Retrospective Study

    by Liyuan Kou, An Song, Min Nie, Yue Jiang, Yingyu Chen, Yiyang Gao, Yan Jiang, Mei Li, Weibo Xia, Ou Wang, et al.

  • Open Access

    Relationship Between Serum Nell‐1 Level and Bone Geometry, Bone Microarchitecture in Chinese Postmenopausal Women

    by Yiyi Gong, Yushuo Wu, Xiang Li, Xiaosen Ma, Xiaolin Ni, Wei Liu, Lijia Cui, Yue Chi, Ruizhi Jiajue, Qianqian Pang, et al.

    Purpose: Neural EGF‐like 1 (Nell‐1), originally implicated in craniosynostosis, has been identified as a key regulator in osteogenic processes. While preclinical data were encouraging, clinical studies correlating serum Nell‐1 levels with osteoporosis remain scarce. This study aims to investigate the relationship between circulation Nell‐1 level and bone turnover markers, bone mineral density (BMD), bone microstructure, muscle strength, fall risk, and fractures in Chinese postmenopausal women. Methods: Serum Nell‐1 levels were measured in 123 Chinese postmenopausal women. Muscle function was evaluated through grip strength tests, the Short Physical Performance Battery (SPPB), and the Timed Up and Go (TUG) test. Dual‐energy X‐ray absorptiometry was used to assess areal bone mineral density (aBMD), lumbar trabecular bone score (TBS), and muscle mass. High‐resolution peripheral quantitative computed tomography (HR‐pQCT) was applied to determine volumetric bone mineral density (vBMD), analyze bone microarchitecture, and estimate bone strength. Result: Postmenopausal women with higher serum Nell‐1 levels had higher aBMD and total volumetric bone mineral density (Tot.vBMD) at the distal tibia, larger cortical area (Ct.Ar) and thicker cortical thickness (Ct.Th) at the distal tibia, and higher bone strength. There was a significant negative association between serum Nell‐1 levels and C‐terminal cross‐linking telopeptide of type I collagen (β‐CTX), while no significant correlations were observed between serum Nell‐1 levels and muscle mass or function. Conclusion: Postmenopausal women with higher serum Nell‐1 levels exhibited higher BMD and bone strength, indicating its potential as a therapeutic invention for osteoporosis.

  • The association of GNAS defects with pro-inflammatory adipokine levels in pseudohypoparathyroidism type 1

    by Yingchun Dong, Yi Yang, An Song, Yan Jiang, Mei Li, Weibo Xia, Fengying Gong, Ou Wang, Xiaoping Xing

  • Efficacy and safety of denosumab biosimilar CMAB807 versus Prolia® in Chinese postmenopausal women with osteoporosis

    by Yan Jiang, Bingwu Wang, Qun Cheng, Yanan Huo, Maozhong Hu, Qin Wang, Li Mao, Hanqing Cai, Lige Song, Ji Hu, et al.


  • Open Access

    Proteomic profiling of bone tissue reveals distinct pathways in men and women with osteoporosis

    by Xiaoyun Lin, Jing Hu, Hengyan Zhang, Lei Sun, Bingna Zhou, Yan Jiang, Ou Wang, Weibo Xia, Jia Zhang, Mei Li

    Background: Osteoporosis is characterised by an imbalance in bone remodelling, yet the detailed molecular mechanisms underlying its pathogenesis remain unclear. This study aimed to identify key proteins and regulatory pathways associated with severe osteoporosis in women and men. Methods: Bone specimens were collected during surgery from 13 women and 12 men with osteoporotic fractures, along with 8 female and 7 male controls with violent fractures. Differentially abundant proteins (DAPs) in bone tissues were identified via nontargeted liquid chromatography–tandem mass spectrometry proteomics. Functional enrichment and pathway analyses were performed; the diagnostic potential of core DAPs was evaluated through multivariate receiver operating characteristic (ROC) analysis, and correlations between DAPs and clinical parameters were assessed. Results: DAPs of women with osteoporotic fractures were primarily associated with immunoinflammatory response, while DAPs of men with osteoporotic fractures were predominantly related to oxidative stress. ROC analysis revealed strong associations between core upregulated proteins and osteoporosis in both women [area under the ROC curve (AUC) = 0.908, 95% confidence interval (CI): 0.676–1] and men (AUC = 0.851, 95% CI: 0.366–1). After adjusting for age, HLA-C in women was significantly negatively correlated with bone mineral density (P < .05), while NDUFA11, COX7A2, NDUFAB1, UQCRC1, COX5A and VDAC1 in men were significantly positively correlated with β-C-terminal telopeptide of type I collagen (P < .05). Conclusion: This study identified sex-specific proteomic profiles and molecular pathways associated with osteoporosis, with ageing emerging as a central upstream driver of these differences. These findings may help elucidate the sex differences in the pathogenesis of osteoporosis and provides a foundation for the discovery of new therapeutic targets and the development of personalised precision treatment strategies.

  • The genetic polymorphism of XPR1 associated with Fanconi syndrome in Chinese patients with X-linked hypophosphatemia

    by Sirui Han, Xiang Li, Wei Liu, Yue Chi, Ruizhi Jiajue, Ziyao Fu, Qianqian Pang, Ou Wang, Mei Li, Xiaoping Xing, et al.

    Purpose X-linked hypophosphatemia (XLH) is the most common type of hereditary hypophosphatemic rickets caused by elevated fibroblast growth factor 23 (FGF23). Multiple cases have reported XLH had Fanconi syndrome (FS) with unidentified mechanism. We investigated the association between genetic polymorphisms of phosphate transporters in renal proximal tubules and XLH with FS for the first time. Methods 25 Chinese XLH patients with FS (XLH-FS) and 33 patients without any urine abnormalities (XLH-nonFS) were included. We collected their clinical manifestations and laboratory results, screened the single-nucleotide polymorphisms (SNPs) of XPR1, SLC34A1 and SLC34A3 by a next generation sequencing-based method, and analyzed the correlation between SNPs and XLH with FS. Computational predictions identified microRNAs (miRNAs) targeting SNPs that influenced susceptibility of FS, and confirmed their interaction and impact on gene expression by a dual-luciferase reporter system. Results XLH-FS group had a higher proportion of trouble walking (88.0% vs 51.5%, p = 0.003). Among the 17 SNPs, rs10494535 located within 3’-UTR region of XPR1 showed significant difference between the two groups. TT/CT genotype and T allele increased susceptibility of FS. Lower luciferase activities were observed in dual-luciferase reporter gene assay as rs10494535 T allele and rs148196667 C allele binding with miRNAs respectively, which implied decreases in XPR1 expression. Conclusion XLH with FS had greater mobility difficulties. The genetic polymorphism of XPR1 was associated with FS in XLH patients. Susceptibility of FS in XLH patients was possibly related to the decrease expression of XPR1 due to the interaction between SNPs and miRNAs.